Eloxatin

Colonic Neoplasms, Colorectal Carcinoma, Colorectal Neoplasms

Treatment

6 FDA approvals

1 Active Study for Eloxatin

What is Eloxatin

Oxaliplatin

The Generic name of this drug

Treatment Summary

Oxaliplatin is a chemotherapy drug used to treat colorectal cancer. It is related to other platinum-based drugs like cisplatin and carboplatin. It is typically used in combination with fluorouracil and leucovorin, known as Folfox. Oxaliplatin has improved anti-tumor activity compared to other platinum-based drugs, as the chlorine ligands are replaced by oxalato bidentate derived from oxalic acid, and the amine groups are replaced by cyclohexyldiamine. This drug is marketed by Sanofi-Aventis under

Eloxatin

is the brand name

image of different drug pills on a surface

Eloxatin Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Eloxatin

Oxaliplatin

2002

91

Approved as Treatment by the FDA

Oxaliplatin, otherwise called Eloxatin, is approved by the FDA for 6 uses including Colorectal Carcinoma and Colorectal Neoplasms .

Colorectal Carcinoma

Used to treat Advanced Colorectal Cancer in combination with Fluorouracil

Colorectal Neoplasms

Used to treat Surgical Resection of the Colorectal Tumor in combination with Fluorouracil

Advanced Colorectal Cancer

Used to treat Advanced Colorectal Cancer in combination with Fluorouracil

Stage III Colon Cancer

Used to treat Stage III Colon Cancer in combination with Fluorouracil

Surgical Resection of the Colorectal Tumor

Used to treat Surgical Resection of the Colorectal Tumor in combination with Fluorouracil

Colonic Neoplasms

Used to treat Stage III Colon Cancer in combination with Fluorouracil

Effectiveness

How Eloxatin Affects Patients

Oxaliplatin stops the body from making DNA. It also affects how much guanine and cytosine are made. When there is a large amount of this drug in the body, it prevents cells from making both RNA and protein.

How Eloxatin works in the body

Oxaliplatin works by attaching itself to the parts of DNA that are made up of guanine and cytosine. This causes the DNA to become linked together, which stops it from replicating and growing. Oxaliplatin does not target any specific cell cycle, so it affects all cells in the body.

When to interrupt dosage

The proposed dosage of Eloxatin is contingent upon the determined condition, such as Stage III Colon Cancer, Colorectal Carcinoma and Colorectal Neoplasms. The measure of dosage is contingent upon the technique of delivery as demonstrated in the table below.

Condition

Dosage

Administration

Colorectal Carcinoma

5.0 mg/mL, , 10.0 mg/mL, 50.0 mg, 100.0 mg, 20.0 mg/mL, 50.0 mg/mL, 100.0 mg/mL

, Intravenous, Injection, solution, concentrate - Intravenous, Injection, solution, concentrate, Powder, for solution - Intravenous, Powder, for solution, Injection, solution - Intravenous, Injection, solution, Injection, powder, lyophilized, for solution - Intravenous, Injection, powder, lyophilized, for solution, Solution - Intravenous, Solution, Injection, Injection - Intravenous, Solution, concentrate - Intravenous, Solution, concentrate

Colonic Neoplasms

5.0 mg/mL, , 10.0 mg/mL, 50.0 mg, 100.0 mg, 20.0 mg/mL, 50.0 mg/mL, 100.0 mg/mL

, Intravenous, Injection, solution, concentrate - Intravenous, Injection, solution, concentrate, Powder, for solution - Intravenous, Powder, for solution, Injection, solution - Intravenous, Injection, solution, Injection, powder, lyophilized, for solution - Intravenous, Injection, powder, lyophilized, for solution, Solution - Intravenous, Solution, Injection, Injection - Intravenous, Solution, concentrate - Intravenous, Solution, concentrate

Colorectal Neoplasms

5.0 mg/mL, , 10.0 mg/mL, 50.0 mg, 100.0 mg, 20.0 mg/mL, 50.0 mg/mL, 100.0 mg/mL

, Intravenous, Injection, solution, concentrate - Intravenous, Injection, solution, concentrate, Powder, for solution - Intravenous, Powder, for solution, Injection, solution - Intravenous, Injection, solution, Injection, powder, lyophilized, for solution - Intravenous, Injection, powder, lyophilized, for solution, Solution - Intravenous, Solution, Injection, Injection - Intravenous, Solution, concentrate - Intravenous, Solution, concentrate

Warnings

Eloxatin Contraindications

Condition

Risk Level

Notes

Pulse Frequency

Do Not Combine

There are 20 known major drug interactions with Eloxatin.

Common Eloxatin Drug Interactions

Drug Name

Risk Level

Description

2-Methoxyethanol

Major

The risk or severity of adverse effects can be increased when Oxaliplatin is combined with 2-Methoxyethanol.

9-(N-methyl-L-isoleucine)-cyclosporin A

Major

The risk or severity of adverse effects can be increased when Oxaliplatin is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A.

Abatacept

Major

The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Abatacept.

Abetimus

Major

The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Abetimus.

Acteoside

Major

The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Acteoside.

Eloxatin Toxicity & Overdose Risk

There have been reports of oxaliplatin overdose in five patients. One patient received two 130 mg/m2 doses within 24 hours and experienced severe low blood platelet count without any bleeding. Two other patients were mistakenly given oxaliplatin instead of carboplatin, one receiving 500 mg and the other 650 mg. Common side effects included difficulty breathing, numbness, vomiting, abnormally low blood platelet count, low red blood cell count, nausea, liver enzyme increase, diarrhea, fatigue and mouth sores. In one case, the patient developed respiratory failure and severe slow heart rate and did not respond to treatment.

image of a doctor in a lab doing drug, clinical research

Eloxatin Novel Uses: Which Conditions Have a Clinical Trial Featuring Eloxatin?

Currently, 5 clinical trials are assessing the effectiveness of Eloxatin in providing relief from Colorectal Neoplasms, Stage III Colon Cancer and Colorectal Carcinoma.

Condition

Clinical Trials

Trial Phases

Colonic Neoplasms

1 Actively Recruiting

Not Applicable

Colorectal Neoplasms

0 Actively Recruiting

Colorectal Carcinoma

0 Actively Recruiting

Eloxatin Reviews: What are patients saying about Eloxatin?

4.3

Patient Review

3/13/2011

Eloxatin for Lymph Node Positive Colon Cancer

I developed long-term peripheral neuropathy as a result of this treatment. Even now, five years later, I'm still dealing with the pain (for which I have to take fentanyl patches and oxycodone). The numbness in my feet makes me clumsy and awkward, and I've even broken my hip - even though there are no signs or symptoms of osteoporosis.

2.7

Patient Review

10/9/2007

Eloxatin for Colon and Rectal Cancer that has Spread to Another Area

I am grateful that this drug has been able to keep my cancer at bay, even if there hasn't been any significant shrinkage. The downside is that it makes me feel very weak and sluggish. I would like to see more information on the long term use and effects of this medication.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about eloxatin

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How is Eloxatin administered?

"Inject ELOXATIN and leucovorin into separate bags, then administer both intravenously over the course of 120 minutes."

Answered by AI

What is Eloxatin used for?

"This medication is used to treat advanced cancer of the colon and rectum. Oxaliplatin is a chemotherapy drug that contains platinum and is used to slow or stop cancer cell growth."

Answered by AI

Is Eloxatin a chemo drug?

"Oxaliplatin is a type of chemotherapy drug that is used to treat bowel cancer and some other types of cancer. It is often given in combination with other chemotherapy drugs."

Answered by AI

Is oxaliplatin a strong chemo?

"Oxaliplatin is the most neurotoxic chemotherapy, which is the origin of peripheral neuropathies. These neuropathies are a problem in oncology because there is no prevention strategy that is effective, and only duloxetine improves symptoms."

Answered by AI

Clinical Trials for Eloxatin

Image of Cedars-Sinai Medical Center in Los Angeles, United States.

Virtual Reality Therapy for Gastrointestinal Cancer Pain

18 - 99
All Sexes
Los Angeles, CA

Patients with digestive tract malignancy often experience severe and unremitting abdominal pain that negatively affects physical, emotional, and social function, as well as health related quality of life (HRQOL). Therapeutic virtual reality (VR) has emerged as a promising and evidence-based treatment modality for cancer pain. Users of VR wear a pair of goggles with a close-proximity screen in front of the eyes that creates a sensation of being transported into lifelike, three-dimensional worlds. To date, VR has been limited to short-term clinical trials for cancer pain. Moreover, limited research exists on theory-based VR modalities beyond mere distraction, such as VR that employs acceptance and commitment therapy (ACT) with components of biofeedback and mindfulness. To bridge these gaps, this study seeks to: (1) assess the impact of immersive VR on patient-reported outcomes (PROs), including pain, activity metrics, and opioid use among patients with visceral pain from a digestive tract malignancy; (2) assess differences in PROs, activity metrics, and opioid use between skills-based VR therapy vs. distraction VR therapy; and (3) determine patient-level predictors of VR treatment response in visceral cancer pain. To address these aims, the study will measure PROs and opioid use in 360 patients randomized among 3 groups and follow them for 60 days after enrollment: (1) an enhanced VR group receiving skills-based VR; (2) a distraction-based VR group receiving patient-selected VR videos; and (3) a VR sham control group using a VR headset with 2-D content. The results will inform best practices for the implementation of VR for visceral cancer pain management and guide selection of patient-tailored experiences.

Recruiting
Device

Cedars-Sinai Medical Center

Brennan Spiegel, MD, MSHS